NCT06917560Active, not recruiting
Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study
The Role of Serological Autoantibody Profiles in the Early Diagnosis and Prognosis of Renal Carcinoma: A Multicenter, Retrospective Clinical Study
Source: ClinicalTrials.gov · Last updated 18 Sept 2025
Brief summary (registry, in English)
This project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. A comprehensive data management system will be established to facilitate the integration and analysis of multicenter data, alongside antibody profiling characteristics. A predictive model based on serological autoantibody profiles will be developed and validated using both internal and external cohorts. This model will predict clinical prognostic factors in renal carcinoma and identify patient populations likely to respond to immunotherapy. By enabling personalized treatment decisions and minimizing unnecessary treatment risks, the model aims to improve patient quality of life and overall prognosis.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 1 Apr 2025
- Start date
- 1 Apr 2025
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Diseases
- Kidney cancer, Childhood cancers
- NCT number
- NCT06917560
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Apr 2025 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Oncological multiplicity: Subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies;
Other illness
- Data insufficiency cohort: Patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.
Lab values
- Biospecimen integrity violation: Cases demonstrating serum hemolysis or compromised specimen integrity;
Other
- Therapeutic contraindication cohort: Individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions;
Who the study is looking for
- Pathological diagnosis of ccRCC;
- Availability of complete clinical, pathological, and follow-up data;
- Sufficient preoperative serum available for collection;
- Well-preserved pathological slides for subsequent immunohistochemical (chip) analysis;
- At least one post-treatment follow-up/efficacy evaluation.
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| first hospital affiliated of Fujian medical university Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.